BfedBwell Proof-of-Concept Pilot

Not Applicable

Active, not recruiting

• Conditions: Cancer Survivorship; Obesity; Overweight
• Interventions: Behavioral: Group-based education and discussion; Behavioral: Group based behavioral skills development and cooking demonstrations; Behavioral: BfitBwell

• Registration Number: NCT06191666
• Lead Sponsor: University of Colorado, Denver

Brief Summary

This single-arm proof-of-concept pilot will assess the feasibility and acceptability of integrating a survivorship nutrition intervention (BfedBwell) into an existing clinical exercise oncology program (BfitBwell).

Detailed Description

Individuals with experience in delivery of lifestyle (e.g., diet, physical activity) interventions will be recruited to deliver and evaluate the integrated BfedBwell + BfitBwell intervention.

Cancer survivors with overweight/obesity who have completed active treatment will be recruited from the University of Colorado Anschutz Medical Campus for participation in a 12-week single-arm study of the integrated BfedBwell + BfitBwell intervention. Feasibility and acceptability will be evaluated. Exploration of intervention effect on adherence to cancer survivorship guidelines, body composition, and cardiometabolic indicators of health will be used to evaluate proof-of-concept prior to advancing to efficacy testing.

Study Timeline

• Study First Submitted: 2023-12-19
• Study First Submitted QC: 2023-12-19
• Study First Posted: 2024-01-05
• Study Start: 2024-02-05
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-19
• Last Update Posted: 2024-07-22
• Primary Completion: 2025-01
• Study Completion: 2026-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

For program delivery staff:

1. Men and women
2. Age ≥ 18 years
3. Speak English
4. Self-reported previous experience in the delivery of nutrition, exercise, or behavioral weight management programs

For intervention participants:

1. Men and women
2. Age 18-75 years
3. Body Mass Index 25-45 kg/m2
4. Completion of active cancer therapy with curative intent at least three months and no more than five years prior to enrollment; ongoing hormone therapy is permitted
5. Have a primary care provider (or are willing to establish care with a primary care provider prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions and who will provide clearance to participate in a nutrition and exercise program
6. Ability and willingness to participate in a supervised exercise program; with ability assessed by the Physical Activity Readiness Questionnaire (PAR-Q+) and questions based upon National Comprehensive Cancer Network guidelines (note: any positive responses will trigger a required physician clearance form)
7. Speak English
8. Have access to a computer or smart phone and Internet
9. Live or work within 30 miles of the Anschutz Health and Wellness Center (exceptions may be made at the discretion of the study PI on a case-by-case basis for highly motivated subjects)
10. Not be planning to travel for >2 consecutive weeks or relocate/move during the intervention
11. Agree to refrain from use of all nutritional supplements aside from those prescribed by a physician for the duration of the study
12. Capable and willing to give informed consent and understand exclusion criteria
13. Willing to attend weekly small group sessions (behavioral skills development and/or group support) and/or 1:1 counseling held by a registered dietitian (RD) and attend up to two BfitBwell exercise sessions per week
14. Not meeting dietary guidelines [i.e., Healthy Eating Index (HEI) score <80 as assessed via National Cancer Institute Diet History Questionnaire III (NCI DHQ III) food frequency questionnaire] or physical activity guidelines [i.e., <150 minutes moderate/vigorous activity per week via self-report on Godin-Shephard Leisure-Time Physical Activity Questionnaire]

Read More

Exclusion Criteria

For program delivery staff:

None

For intervention participants:

1. Eastern Cooperative Oncology Group (ECOG) Performance Status 2 or higher

2. Actively undergoing cancer therapy or within 3 months of completion of surgery, chemotherapy, or radiation treatment

3. Greater than 5 years post-active therapy

4. Plans to relocate within the next 6 months

5. Plans for extended travel (>2 weeks) within the next 6 months

6. For females:

   1. Currently pregnant or lactating
   2. Pregnant within the past 6 months
   3. Planning to become pregnant in the next 18 months; sexually active women of childbearing potential may be enrolled if they have had a tubal ligation or use a reliable means of contraception

7. Any major surgery within the past 3 months, including mastectomy

8. Have completed treatment that significantly impacts digestion, metabolism, and/or food intake (e.g., surgical loss of esophagus, stomach, colon)

9. Recent (past 6 months) acute coronary event, unstable angina, coronary revascularization, stroke, or pulmonary embolism

10. Symptoms suggestive of cardiovascular disease (e.g., chest pain, shortness of breath at rest or with mild exertion, lightheadedness, syncope)

11. Uncontrolled hypertension, defined as diastolic blood pressure >100 mmHg, systolic blood pressure >160 mmHg, or resting heart rate >100 bpm as measured in duplicate on the screening visit after 5 minutes of rest in a seated position (if screening is needed due to lack of updated medical record within previous 12 months)

12. Diabetes (history of type 1 or type 2 diabetes, hemoglobin A1c >7.5%, or fasting glucose ≥126 mg/dL as measured during the screening visit if screening is needed due to lack of updated medical record within previous 12 months) unless well controlled on metformin alone

13. History of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen is acceptable

14. Triglycerides >500 mg/dL as measured on the screening visit (if screening is needed due to lack of updated medical record within previous 12 months)

15. LDL cholesterol >200 mg/dL as measured on the screening visit (if screening is needed due to lack of updated medical record within previous 12 months)

16. Presence or history of other metabolic or chronic health problems which would impact ability to safely participate in a weight loss intervention involving diet and exercise: significant cardiac arrhythmias or cardiac valvular disease, significant gastrointestinal, pulmonary, renal, musculoskeletal, neurologic, hematologic, or psychiatric disease

17. Have started lipid-lowering, hypertension, or oral hypoglycemic medication in previous 3 months

18. Sustained use of prescription or over-the-counter medications known to significantly impact appetite, weight, or energy metabolism (e.g., obesity pharmacotherapeutics agents, appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants) with the exception of anti-endocrine or Her2 directed treatment for breast cancer and standard of care anti-emetic or anti-diarrheal agents.

19. Sustained use of systemic glucocorticoids (current or in the past 6 months) unless physiologic replacement therapy for adrenal insufficiency

20. Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed >1 year before screening, (2) lap banding if the band has been removed >1 year before screening, (3) intragastric balloon if the balloon has been removed >1 year before screening, (4) duodenal-jejunal bypass sleeve if the sleeve has been removed >1 year before screening, or (5) AspireAssist or other endoscopically placed weight loss device if the device has been removed >1 year before screening

21. Participation within previous 6 months, current participation in, or planning to participate in any formal nutrition, weight loss, or physical activity programs or clinical trials over the next 6 months

22. Previous participation the BfitBwell exercise oncology program

23. Current alcohol or substance abuse as assessed by the Cut down, Annoyed, Guilty, and Eye-Opener (CAGE) questionnaire (note: study PI will follow up if screener raises any concerns of substance abuse to determine final eligibility)

24. History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Score >20 on the Eating Attitudes Test (EATS-26) or pattern of response on the Questionnaire of Eating and Weight Patterns (QEWP-5) suggestive of possible binge eating disorder or bulimia will require further assessment by the study MD to determine if it is appropriate for the subject to participate in the study

25. Current severe depression or history of severe depression within the previous year, based on Center for Epidemiologic Studies Depression Scale (CES-D)

26. History of other significant psychiatric illness (e.g., psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the study MD would interfere with ability to adhere to the diet and exercise interventions

27. Have medical or physical limitations or contraindications to engaging in physical activity (e.g., severe orthopedic conditions, paralysis) or are considered high-risk based on American College of Sports Medicine (ACSM) guidelines

28. Are cognitively unable to consent

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cancer Survivors	Group based behavioral skills development and cooking demonstrations	Cancer survivors with ow/ob who have completed active treatment will take part in a single-arm 12-week feasibility/acceptability/proof-of-concept study incorporating group nutrition education and discussion, skills development sessions and cooking demonstrations, and 1:1 counseling with a dietitian.
Cancer Survivors	Group-based education and discussion	Cancer survivors with ow/ob who have completed active treatment will take part in a single-arm 12-week feasibility/acceptability/proof-of-concept study incorporating group nutrition education and discussion, skills development sessions and cooking demonstrations, and 1:1 counseling with a dietitian.
Cancer Survivors	BfitBwell	Cancer survivors with ow/ob who have completed active treatment will take part in a single-arm 12-week feasibility/acceptability/proof-of-concept study incorporating group nutrition education and discussion, skills development sessions and cooking demonstrations, and 1:1 counseling with a dietitian.

Primary Outcome Measures

Name	Time	Method
Determine the intervention acceptability by program delivery staff using Intervention Appropriateness Measure (IAM)	12 weeks	Upon completion of the intervention, program delivery staff will be asked to complete the Intervention Appropriateness Measure (IAM). A Likert scale from 1 (completely disagree) to 5 (completely agree) is used for each question; higher scores indicate greater intervention appropriateness.
Determine the research protocol adherence feasibility of the BfedBwell nutrition intervention	12 weeks	Adherence will be assessed as \[# sessions attended/# sessions provided\]
Determine the research protocol retention feasibility of the BfedBwell nutrition intervention	12 weeks	Retention will be assessed as \[# of participants who complete the 12-week intervention/# of participants enrolled\].
Determine the intervention acceptability by program delivery staff using Acceptability of Intervention Measure (AIM)	12 weeks	Upon completion of the intervention, program delivery staff will be asked to complete the Acceptability of Intervention Measure (AIM). A Likert scale from 1 (completely disagree) to 5 (completely agree) is used for each question; higher scores indicate greater intervention acceptability.
Determine the research protocol recruitment feasibility of the BfedBwell nutrition intervention	12 weeks	Recruitment will be assessed as the number of adults screened and the proportion of eligible screens who enroll.
Determine the research protocol outcome assessment feasibility of the BfedBwell nutrition intervention	12 weeks	Outcome assessment rates will be assessed as \[# completing assessments/# enrolled\].
Determine the intervention feasibility by program delivery staff using Feasibility of Intervention Measure (FIM)	12 weeks	Upon completion of the intervention, program delivery staff will be asked to complete the Feasibility of Intervention Measure (FIM). A Likert scale from 1 (completely disagree) to 5 (completely agree) is used for each question; higher scores indicate greater intervention feasibility.
Determine the intervention acceptability by participants using the Net Promoter Score (NPS)	12 weeks	Participants will be asked to complete weekly ratings using the Net Promoter Score (NPS). Respondents are grouped as follows: 1) promoters (score 9-10) are loyal enthusiasts who will keep referring others and fueling growth, 2) passives (score 7-8) are satisfied but unenthusiastic customers who are vulnerable to competitive offerings, and 3) detractors (score 0-6) are unhappy customers who can impede growth with negative word-of-mouth. The final NPS score is calculated as % promoters - % detractors. NPS scores range from -100 to +100, with scores \>0 indicating good acceptability.
Determine the intervention acceptability by participants and program providers during qualitative interviews	12 weeks	1:1 interviews will be conducted with all program delivery staff and BfedBwell survivorship nutrition intervention participants after the 12-week intervention to assess acceptability of intervention and provide feedback for continued refinement.

Secondary Outcome Measures

Name	Time	Method
Measure the change in systolic blood pressure to determine improved cardiometabolic health	12 weeks	Systolic blood pressure will be measured at specific time points during the trial. A lower systolic blood pressure indicates an improvement.
Measure changes in HDL cholesterol to determine improved cardiometabolic health	12 weeks	HDL cholesterol will be measured at specific time points during the trial. A higher HDL cholesterol indicates an improvement.
Intervention safety determined by number of adverse events	12 weeks	Overall rates of study-related mild, moderate, severe, and serious adverse events (AEs) will be tracked by study staff.
Measure changes in triglycerides to determine improved cardiometabolic health	12 weeks	Triglycerides will be measured at specific time points during the trial. Lower triglycerides indicate an improvement.
Measure changes in glucose to determine improved cardiometabolic health	12 weeks	Glucose levels will be measured at specific time points during the trial. Lower glucose levels indicate an improvement.
Measure changes in insulin to determine improved cardiometabolic health	12 weeks	Insulin levels will be measured at specific time points during the trial. Lower insulin levels indicate an improvement.
Assess preliminary efficacy for increased adherence to lifestyle recommendations	12 weeks	Determine the change in adherence to cancer survivorship guidelines as measured by World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) scoring criteria. Scores range from 0 to 7 points. A higher score reflects greater adherence to the recommendations.
Assess preliminary efficacy for weight loss	12 weeks	Determine the change in weight as measured by digital scale. A lower weight indicates an improvement.
Measure the change in diastolic blood pressure to determine improved cardiometabolic health	12 weeks	Diastolic blood pressure will be measured at specific time points during the trial. A lower diastolic blood pressure indicates an improvement.
Measure changes in total cholesterol to determine improved cardiometabolic health	12 weeks	Total cholesterol will be measured at specific time points during the trial. A lower total cholesterol indicates an improvement.
Measure changes in LDL cholesterol to determine improved cardiometabolic health	12 weeks	LDL cholesterol will be measured at specific time points during the trial. A lower LDL cholesterol indicates an improvement.
Assess preliminary efficacy for improvement in body composition	12 weeks	Determine the change in body composition as measured by dual x-ray absorptiometry (DXA). A lower body fat percentage indicates an improvement.

Trial Locations

Locations (1)

University of Colorado Cancer Center; 🇺🇸 Aurora, Colorado, United States